BRIEF: Joinn Lab swings to red on lower revenue, falling gross margin

6127.HK 603127.SHG

Joinn Laboratories (China) Co. Ltd. (6127.HK; 603127.SH), China’s leading non-clinical contract research organization (CRO), said on Wednesday its revenue fell 15.5% to 486 million yuan ($68.3 million) in the third quarter, while its net profit tumbled 58% to 99.44 million yuan.

The company reported a net loss of 70.31 million yuan for the first three quarters of the year, reversing a profit of 328 million yuan in the same period of last year, mainly due to intensified competition in the industry, falling sales and a declining gross margin, as well as a drop in the fair value of its biological assets.

Joinn’s Hong Kong-listed shares rose 1.7% to HK$8.99 in early Thursday trade.

By A. Au

To subscribe to Bamboo Works free weekly newsletter, click here

,
,

Related Articles

RELATED ARTICLES

  1. BRIEF: Tianqi swings to red on falling lithium prices
    9696.HK 002466.SHE
  2. Dida reverses into revenue contraction, falling profits
    2559.HK
  3. Vanke bleeds red ink but detects signs of upturn
    2202.HK 000002.SHE
  4. BRIEF: C-MER swings to the red on $26 million in charges
    3309.HK
  5. Butong navigates twin challenges of falling birthrates, weak consumption
  6. Did falling durian prices undermine an already-shaky Hongjiu Fruit?
    6689.HK
  7. BRIEF: JinkoSolar returns to the black as revenue keeps falling
    JKS.US 688223.SHG
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

Recent Articles

Illustration of the rebound of Chinese fintech lenders

A fintech lender rebound, and a hotel mess

Fintech lenders are entering a new golden era, with Jiayin reporting 46% growth for its core consumer lending business in last year's fourth quarter and forecasting similar gains this year. What's driving this rebound? And hotelier H World is still trying to fix a German acquisition from 2019 that wiped out its profit in the fourth quarter of last year. Will the Chinese hotelier be able to turn around this money-losing offshore asset?
JFIN.US HTHT.US